Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SEMINAR
February 26, 2007
- TOPIC about Novo Nordisk Pharma
February 26, 2007
- Regulatory Systems in Japan Need Improvements in 5 Areas: Mr Dunoyer of EFPIA Japan
February 26, 2007
- Pfizer J-GAP Survey
February 26, 2007
- New Review, Consultation Fees Proposed
February 26, 2007
- DSP Is Seeing Synergistic Effects: President Miyatake
February 26, 2007
- Toxicogenomics Research Project
February 26, 2007
- R&D NEWS IN BRIEF
February 19, 2007
- New Mitsubishi Tanabe to Strengthen Drug Discovery, Global Presence
February 19, 2007
- Merck, Bristol-Myers Submit NDA for Erbitux
February 19, 2007
- Kirin Pharma to Create 500-MR System in 2007
February 19, 2007
- Three Vaccine Makers Apply for Approval of Pre-pandemic Flu Vaccine
February 19, 2007
- Eli Lilly, Shionogi to Codevelop, Comarket Duloxetine in Japan
February 19, 2007
- Japan, EU Reach Agreement on Confidentiality of Drug Information
February 19, 2007
- Chugai: Sales, Profits Impacted by NHI Price Cuts
February 19, 2007
- REGULATORY NEWS IN BRIEF
February 19, 2007
- Companies Gearing Up for Pollinosis Season
February 19, 2007
- Sawai's New 3-Year Plan to Focus on New Formulations, Data Supply
February 19, 2007
- BUSINESS NEWS IN BRIEF
February 19, 2007
- Nihon Chouzai: Profits Hit By GE Drug Promotion Costs
February 19, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…